Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma Michael S. Sabel, Vernon K. Sondak Oncologist 2003; 8: 451-458 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in melanoma and cutaneous malignancies and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Define the indication for and administration of IFN- in the adjuvant treatment of melanoma. Explain the rationale both for and against the use of adjuvant interferon. Discuss areas of ongoing research for adjuvant therapy of melanoma. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 7, 2003 Most Recent Review: Oct. 7, 2003* Most Recent Update: Oct. 7, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.